Compare ROCK & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROCK | COLL |
|---|---|---|
| Founded | 1972 | 2002 |
| Country | United States | United States |
| Employees | 2221 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 1996 | 2015 |
| Metric | ROCK | COLL |
|---|---|---|
| Price | $39.76 | $36.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $50.83 |
| AVG Volume (30 Days) | 288.2K | ★ 430.2K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | ★ $1,135,501,000.00 | $780,567,000.00 |
| Revenue This Year | $24.00 | $5.93 |
| Revenue Next Year | $34.38 | N/A |
| P/E Ratio | ★ N/A | $20.12 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $37.80 | $23.23 |
| 52 Week High | $75.08 | $50.79 |
| Indicator | ROCK | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 30.35 | 34.67 |
| Support Level | $37.80 | $34.29 |
| Resistance Level | $51.86 | $39.85 |
| Average True Range (ATR) | 1.66 | 1.31 |
| MACD | -0.10 | -0.12 |
| Stochastic Oscillator | 27.56 | 27.86 |
Gibraltar Industries Inc manufactures and provides products and services for the Renewable energy, Residential, Agtech, and Infrastructure markets. The Renewables Segment is engaged in designing, engineering, manufacturing, and installing solar racking and electrical balance systems. Agtech Segment provides growing and processing solutions including the designing, engineering, manufacturing, full-scope construction, maintenance, and support of greenhouses and indoor growing operations, and botanical extraction systems. It derives key revenue from the Residential segment which offers roof and foundation ventilation products, single point and centralized mail systems electronic package solutions, and Retractable awnings and gutter guards, among other products.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.